Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR alfa beta depleted HSCT in pediatric hematological disorders
NCT01810120Phase 2Completed
- Start
- Jan 2012
- Primary completion
- Sep 2016
- Countries
- 1
01
Overview
Phase 2, open-label trial of TCR alpha beta T cell depletion in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and 5 more. Primary endpoint: CD34+ cells at 3 months. Started Jan 2012; status: completed.
02
Drugs
TCR alpha beta T cell depletion
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)myelodysplastic syndrome (MDS)severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NCT01810120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01810120.